Immunogenicity Summit
Immunogenicity and Bioassay Summit

Cambridge Healthtech Institute’s Eighth Annual
Immunogenicity Prediction & Control
Contributory Factors, Predictive Tools, Clinical Correlations, Management, and Tolerance Induction

   October 27-28, 2016 | Hyatt Regency Baltimore | Baltimore, Maryland

Part of CHI's Immunogenicity and Bioassay Summit 2016

Loss of efficacy and potential cross-reactivity resulting from immunogenicity is a huge burden on the industry. Moreover immunogenicity denies patients life-saving treatments. Immunogenicity Prediction & Control will examine the factors that contribute to immunogenicity, such as epitopes, impurities, and the route of administration, reveal the methods the pioneers use to predict immunogenicity, and present approaches  for reducing immunogenicity for specific products, and for  immune suppression and tolerance induction. This conference will provide case studies from experts in the field and opportunities for attendees to share their experiences.

Who should attend: CHI's Immunogenicity Prediction and Control conference will bring together individuals from regulatory affairs, bioanalytical development, clinical and non-clinical immunology, PKPD, pharmacology, toxicology, safety and R&D.   

I am looking for case studies on the following:

  • Risk factors that contribute to immunogenicity: including product characteristics, chemical modification, impurities, epitopes, and component peptides, and impact of production, purification, formulation, dosing and storage.
  • Current tools and approaches for immunogenicity risk prediction: such as in silico and in vitro approaches, new tools and novel approaches.
  • Experiences with different mouse models for predictive studies: knock-in, knock-out, humanized, partially humanized, etc.
  • Impact of different routes of administration on immunogenicity
  • The impact of sub-visible particles, aggregates and impurities on immunogenicity: including detection and control of impurities and aggregate formation, evidence that they act as adjuvants, and immunological mechanisms.
  • Correlations between predictive immunogenicity and the clinical outcome
  • Measures to control immunogenicity of specific products: such as bispecifics, ADCs, enzymes, interferons, pegylated proteins etc.
  • Progress towards inducing immunological tolerance to biotherapeutics, deimmunization approaches and strategies for inducing tolerance

Proposed short courses:

  • Basics of Immunogenicity
  • Overcoming the Challenges of Immunogenicity Assessment
  • Immunogenicity Risk Assessment and Regulatory Strategy
  • Strategic Bioassay Design and Analysis

If you would like to submit a proposal to give a presentation at this meeting, please click here.

Deadline for submission is April 6, 2016  

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Nicole Lyscom Ph.D.
Senior Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489

For exhibit and sponsorship opportunities, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Tel: 1 781-972-5412

For media and association partnerships, please contact:
James Prudhomme
Senior Marketing Manager
Cambridge Healthtech Institute
Tel: 781-972-5472

Register Today!

Submit A Speaker Proposal

Download 2015 Brochure

IMN 2015 Brochure Download  

View All Sponsors Big

View Attendee List Big

View Media Partners Big